VIVUS (VVUS), Auxilium Announce Extension of STENDRA License Termination Data

August 29, 2016 4:31 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

VIVUS, Inc. (Nasdaq: VVUS) and Auxilium Pharmaceuticals, Inc., a subsidiary of Endo International plc (Nasdaq: ENDP) announced an extension of the termination date of the license agreement between Auxilium and VIVUS for STENDRA® (avanafil) U.S. and Canadian commercial rights through September 30, 2016.

"We have been working closely with Auxilium to ensure a smooth transition of STENDRA back to VIVUS," said Seth H. Z. Fischer, VIVUS Chief Executive Officer. "Through this process, we have determined that a handoff of STENDRA at the end of a calendar quarter provides the most efficient cut-off date for our internal processes, customers and vendors. We are concurrently preparing to commercialize STENDRA in the U.S. while maintaining discussions to license or sell STENDRA's U.S. commercialization rights."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation, Management Comments

Add Your Comment